1. What is the difference between Parkinson’s dementia and Alzheimer’s disease in terms of symptoms? A: First of all, patients with Parkinson’s dementia are in Parkinson’s disease motor symptoms such as bradykinesia, tremor, muscle tonicity after the appearance of dementia performance; secondly, Parkinson’s dementia is mainly characterized by subcortical dementia, highlighted by executive function, attention and visual-spatial ability decreases, memory impairment and vocabulary expression fluency decreases, language function, orientation is relatively preserved, and the fluctuation of cognitive impairment is usually an important basis for the diagnosis of Parkinsonian dementia; Alzheimer’s disease is dominated by cortical dementia, with significant memory storage, orientation, and language impairment in the early stages of the disease. 2. What are the differences in imaging findings between Parkinson’s dementia and Alzheimer’s dementia in terms of imaging examinations, such as MRI and CT examinations? A: Parkinson’s dementia usually has no significant abnormalities on CT or MRI, with only signs of age-related brain atrophy or white matter hyperintensities. In MRI diffusion tensor imaging (DTI) patients with PD have significantly lower mass fraction anisotropy (FA) values, especially in the mass tail. In Alzheimer’s disease patients, hippocampal atrophy and limited cortical atrophy in the language area were seen in the coronal plane of MRI. 3.What is the difference between Parkinson’s dementia and Alzheimer’s disease in terms of treatment? A: Parkinson’s dementia is firstly treated with the choice of anti-Parkinson’s disease. The choice of drugs is based on levodopa-like agents as the first-line drugs. If other anti-Parkinson’s disease drugs are used, there is a risk of inducing psychiatric symptoms, and attention should be paid to the dosage and method of use. If patients with Parkinson’s dementia experience hallucinations and delusions, dose reduction or discontinuation of anticholinergic drugs, amantadine, dopamine agonists, MAO-B inhibitors, should be considered in turn; cholinesterase inhibitors, such as carbaplatin and donepezil, can also be used in the treatment of cognitive impairment. Alzheimer’s disease is given pharmacological treatment, drugs including cholinesterase inhibitors, excitatory amino acid receptor antagonists, brain metabolism enhancers, etc. 4.What is the difference between the prognosis of Parkinson’s dementia and Alzheimer’s dementia? A: About 50-80% of Parkinson’s patients will have a combination of Parkinson’s disease dementia, which usually occurs 3-7 years after the onset of motor symptoms in Parkinson’s disease, so it is often accompanied by significant motor symptoms such as bradykinesia, limb straightening, etc. It is usually believed that patients with Parkinson’s disease gradually lose their mobility and become bedridden 15-20 years after diagnosis, which leads to some fatal complications, such as severe lung infections, urinary tract infections, lower limb venous hemorrhage, etc. urinary tract infections, lower extremity venous thrombosis, pulmonary embolism, etc. In the case of Alzheimer’s disease, it is usually believed that severe memory loss occurs about 8-12 years after the onset of cognitive decline, with only fragments of memory remaining; about 30% of patients also develop Parkinson’s-like symptoms and gradually become unable to care for themselves in daily life, incontinent, bedridden, etc. Some fatal complications also occur, such as lung infections, urinary tract infections, and other bedridden complications, and patients usually die from Complications.